Vanda Pharmaceuticals Inc. (LON:0LKB)

London flag London · Delayed Price · Currency is GBP · Price in USD
5.05
+0.08 (1.60%)
At close: Dec 3, 2025
3.45%
Market Cap239.08M
Revenue (ttm)157.77M
Net Income (ttm)-62.64M
Shares Outn/a
EPS (ttm)-1.07
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume6,190
Average Volume15,510
Open5.00
Previous Close4.97
Day's Range4.93 - 5.05
52-Week Range3.83 - 5.64
Betan/a
RSI63.69
Earnings DateFeb 12, 2026

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2002
Employees 368
Stock Exchange London Stock Exchange
Ticker Symbol 0LKB
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.